My key area of interest is in cancer and the tumour microenvironment, especially in ovarian cancer. I study the links between cancer and inflammation and research ways of translating this to clinical trials.
We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.
Our group focuses on understanding the molecular and cellular mechanisms that mediate resistance to anti-cancer therapies in breast cancer. We are interested in dissecting the microenvironmental cues that orchestrate specific tumour responses and metastasis formation.
My group studies how different populations of immune cells in the tumour microenvironment cross-talk in order to establish a tumour-supportive niche in metastasis. This research aims to identify more effective therapeutic targets in metastatic cancers.
Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
My research is focused on the tumour microenvironment of ovarian cancer with a particular focus on the extracellular matrix and how current and novel treatments influence this microenvironment.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
My research focuses on exploring why ASS1 is differently expressed in human cancers and how this information may be transferred for anticancer therapy.